AlphAIAlphAI — Financial news for AI agents
stocktitan.netSEP 171 min read$HIMS

Officer at Hims & Hers (NYSE: HIMS) plans $355K stock sale

Hims & Hers (HIMS) officer Oluyemi Okupe plans to sell 12,313 Class A shares, valued at $354,860.66, on September 17, 2026. The shares were acquired via restricted stock vesting on August 15, 2026. As of September 17, 2026, HIMS had 224,935,790 Class A shares outstanding.

Original reporting
stocktitan.net
Published Sep 17, 2026, 7:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 9:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$HIMS
Neutral
high confidence
Mentioned
$HIMS
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$HIMSNeutralLow
01

Why it matters

The filing adds a modest amount of shares to the market, but the amount is trivial relative to total shares outstanding.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Potential future insider sales if more vesting occurs.

Relevance 4/10Novelty 3/10Timing: Sep 17, 2026 filing date

Background

Form 4 disclosures are required for insiders to report sales of restricted stock.

Company-level read

Ticker impact

$HIMSNeutralHigh confidence
Context

Officer Oluyemi Okupe filed a Form 4 to sell 12,313 shares worth $354,861 on Sep 17, 2026.

Expected impact

No significant impact expected.

Evidence & confidence

Sale size is small relative to float and market cap.

Market effects

Sector

None; insider sale does not affect sector trends.

Regional

None; limited to Hims & Hers investors.

Global

None

Counterpoint

What could challenge this read

If the officer is signaling lack of confidence, some may view it as a bearish cue.

Key entities

  • Officer
    Oluyemi Okupe

    Officer at Hims & Hers filing the sale.

  • Company
    Hims & Hers Health, Inc.

    US-listed telehealth company (NYSE:HIMS).

Read at source← All news

Related articles

SEP 22
$HIMSMed

Hims & Hers Suit Spotlights Health Data-Sharing Privacy Risks

The FTC, along with California and Utah regulators, filed a lawsuit against Hims & Hers on July 29, alleging privacy risks related to health data-sharing. The complaint was filed in the U.S. District Court for the Northern District of California. This legal action highlights concerns over consumer data protection in the health sector.

law360.com1 min
SEP 19
$HIMSMed

Telehealth companies keep exposing their customers' medical data. What should they do?

The FTC sued Hims & Hers for allegedly disclosing customer health data, signing users up for hard-to-cancel subscriptions, and bypassing real-time doctor consultations. Hims disputes the claims. Experts note federal laws often don't apply to telehealth companies, leading to data sharing with advertisers. Recent studies found many telehealth services lack proper physician consultations, especially for GLP-1 drugs. State laws offer some protections, but enforcement is limited. Privacy experts reco

newsday.com2 min
SEP 18
$HIMSHighAI 8/10

Class-action lawsuit filed against Hims & Hers following FTC complaint

A class-action lawsuit was filed against Hims & Hers (HIMS) on behalf of investors who acquired securities between 4 August 2025 and 29 July 2026, following an FTC complaint. The FTC alleges deceptive billing and unlawful sharing of health information. HIMS shares fell 14.73% on the news, closing at $25.00. The company denies the allegations.

dig.watch2 min
SEP 17
$HIMSHighAI 8/10

HIMS Stock Snaps 2-Day Climb: Analyst Says Record Subscriber Growth ‘Not Enough’ To Offset Margin Slide

Hims & Hers Health (HIMS) stock fell 4% on Tuesday despite record subscriber growth and a Q2 revenue beat. Revenue rose 38% to $753M, but adjusted EBITDA dropped 27% to $60.3M. Morningstar noted margin concerns, while Deutsche Bank raised its price target to $26. The company raised its 2026 revenue forecast but lowered its EBITDA guidance.

stocktwits.com2 min
SEP 14
$HIMSMed

Why Hims & Hers Stock Is Suddenly Soaring

Hims & Hers Health (HIMS) stock surged following a $32 price target from JPMorgan, which projects $1.1B in GLP-1 weight-loss revenues by 2026. The rally was also driven by a new 3x leveraged long product on the LSE. The company has 3M subscribers and growing revenue, but faces debt and margin pressures.

tipranks.com2 min
SEP 11
$HIMSMed

JPMorgan cautious on Hims & Hers on GLP-1 transition risk

JPMorgan initiated coverage of Hims & Hers Health with a Neutral rating and a $32 price target for 2027. The firm acknowledges the company's growth but highlights risks in its transition to branded weight-loss drugs. Hims has 2.9 million subscribers and a partnership with Novo Nordisk for Wegovy shipments. JPMorgan projects 2026 GLP-1 revenue of $1.1 billion and long-term revenue growth to over $6.5 billion by 2030, but cautions on execution risks.

investing.com2 min